QQ客服 官方微博 反馈留言

	A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy naive patients with mCRPC in China, Malaysia, Thailand and Russia
	Ye, Dingwei; Huang, Yiran; Zhou, Fangjian; Xie, Keji; Matveev, Vsevolod; Li, Changling; Alexeev, Boris; Tian, Ye; Qiu, Mingxing; Li, Hanzhong
刊名	ASIAN JOURNAL OF UROLOGY
	2017
卷号	4期号:2
关键词	Abiraterone Chemotherapy-naive Metastatic castration-resistant prostate cancer Prostate specific antigen Prednisone
ISSN号	2214-3882
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3618850
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Ye, Dingwei,Huang, Yiran,Zhou, Fangjian,et al. A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy naive patients with mCRPC in China, Malaysia, Thailand and Russia[J]. ASIAN JOURNAL OF UROLOGY,2017,4(2).
APA	Ye, Dingwei.,Huang, Yiran.,Zhou, Fangjian.,Xie, Keji.,Matveev, Vsevolod.,...&Sun, Yinghao.(2017).A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy naive patients with mCRPC in China, Malaysia, Thailand and Russia.ASIAN JOURNAL OF UROLOGY,4(2).
MLA	Ye, Dingwei,et al."A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy naive patients with mCRPC in China, Malaysia, Thailand and Russia".ASIAN JOURNAL OF UROLOGY 4.2(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。